edoc

Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum

Genton, B. and D'Acremont , V. and Lurati-Ruiz , F. and Verhage, D. and Audran, R. and Hermsen, C. and Wolters, L. and Reymond, C. and Spertini, F. and Sauerwein, R.. (2010) Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum. Vaccine, 28 (40). pp. 6573-6580.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/45714/

Downloads: Statistics Overview

Abstract

The aim of this Phase I/IIa double-blind controlled trial was to test the efficacy of the sporozoite-based malaria vaccine PfCS 282-383 (PfCS102) to protect against Plasmodium falciparum parasitaemia. 16 volunteers were randomized to receive twice 30mug of PfCS102 formulated in Montanide ISA 720 or ISA 720 alone (control). Two weeks after 2nd immunization, volunteers were challenged using 5 infected mosquitoes. All vaccinees developed antibodies against PfCS102 versus none control. 8/8 vaccinees and 6/6 controls challenged developed malaria parasitaemia. The duration from infection to onset of patent parasitaemia was similar in both groups (214h in vaccinees and 216 in controls). PfCS102 is safe and immunogenic but provides no protection against artificial challenge in its current formulation
Faculties and Departments:09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Epidemiology and Public Health (EPH) > Health Interventions > Malaria Interventions (Lengeler)
UniBasel Contributors:Genton, Blaise and D'Acremont, Valérie
Item Type:Article, refereed
Publisher:Elsevier
ISSN:0264-410X
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:03 Nov 2017 12:34
Deposited On:05 Jan 2017 10:18

Repository Staff Only: item control page